Valneva Announces up to $500 Million Debt Facility With Pharmakon Advisors
San Francisco – October 6, 2025 – Cooley advised Valneva, a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs, on a debt facility for up to $500 million in nondilutive financing with funds managed by Pharmakon Advisors. An initial tranche of $215 million will be used to repay in full Valneva’s existing debt facility with Deerfield Management and OrbiMed, inclusive of associated fees and expenses. The remaining up to $285 million may be drawn in the future for potential business development subject to mutual agreement between the parties.
Lawyers Gian-Michele a Marca, Shimeng Cheng, Amanda Fant and Kavi Huded led the multidisciplinary Cooley team advising Valneva. Others on the team included capital markets partners Katie Kazem and Marc Recht, patent counseling and prosecution partner Jonathan Cousin, life sciences partner Christophe Beauduin and special counsel Rena Kaminsky, and tax partner Xander Lee.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.